The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma

Stem Cells Translational Medicine

Volumn 2, Issue 9, 2013, Pages 655-666

  Tobias, Alex L ^a   Thaci, Bart ^a   Auffinger, Brenda ^a   Rincón, Esther ^a   Balyasnikova, Irina V ^a   Kim, Chung Kwon ^a   Han, Yu ^a   Zhang, Lingjiao ^a   Aboody, Karen S ^b   Ahmed, Atique U ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Chemotherapy; Gene therapy; Glioma; Neural stem cell; Radiation; Temozolomide; Virotherapy

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; HERMES ANTIGEN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SOX2; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FETUS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; VIROTHERAPY; VIRUS REPLICATION; WESTERN BLOTTING; WOUND HEALING;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 84883438714     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0039     Document Type: Article

References (47)

1. Xu DS, Yang C, Proescholdt M et al. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS One 2012;7: e37811.
2. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17:417-421.
3. Thumma SR, Elaimy AL, Daines N et al. Longterm survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: A case report and review of the literature. Case Report Med2012;2012:545492.
4. Rahman R, Smith S, Rahman C et al. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010; 2010:251231.
5. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16:2443-2449.
6. Liu C, Zong H. Developmental origins of brain tumors. Curr Opin Neurobiol 2012;22:844-849.
7. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
8. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancerstemcells:Muchmorecomplex than expected. Mol Cancer 2011;10:128.
9. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: A review. J Neurosci Res 2009;87:2183-2200.
10. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97:12846-12851.
11. Ulasov IV, Zhu ZB, Tyler MA et al. Survivin- driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007;18:589-602.
12. Thaci B, Ahmed AU, Ulasov IV et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: Targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 2012;19:431-442.
13. Ahmed AU, Thaci B, Alexiades NG et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 2011;19:1714-1726.
14. Chatrchyan S, Khachatryan V, Sirunyan AM et al. Search for supersymmetry in pp collisions at √7 TeV in events with two photons and missing transverse energy. Phys Rev Lett 2011;106:211802
15. Ahmed AU, Ulasov IV, Mercer RW et al. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol 2012;797:97-109.
16. Tyler MA, Ulasov IV, Sonabend AM et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009;16:262-278.
17. Kanai R, Rabkin SD, Yip S et al. Oncolytic virus-mediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012;104:42-55.
18. Karapanagiotou EM, Roulstone V, Twigger K et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18:2080-2089.
19. Immonen A, Vapalahti M, Tyynela K et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 2004;10:967-972.
20. Kim SU, Nagai A, Nakagawa E et al. Production and characterization of immortal human neural stem cell line with multipotent differentiation property. Methods Mol Biol 2008; 438:103-121.
21. Kim SK, Kim SU, Park IH et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006;12:5550-5556.
22. Sonabend AM, Ulasov IV, Han Y et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: A comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 2009;16:362-372.
23. Beier D, Rohrl S, Pillai DR et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008;68: 5706-5715.
24. Rosso L, Brock CS, Gallo JM et al. A new model for prediction of drug distribution in tumor and normal tissues: Pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009;69:120-127.
25. Brada M, Judson I, Beale P et al. Phase I doseescalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-1030.
26. Ostermann S, Csajka C, Buclin T et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-3736.
27. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
28. Ahmed AU, Lesniak MS. Glioblastoma multiforme: Canneuralstemcells deliverthetherapeutic payload and fulfill the clinical promise? Expert Rev Neurother 2011;11:775-777.
29. Sarkaria JN, Carlson BL, Schroeder MA et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-2271.
30. Giannini C, Sarkaria JN, Saito A et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005;7:164-176.
31. Ottolino-Perry K, Diallo JS, Lichty BD et al. Intelligent design: Combination therapy with oncolytic viruses. Mol Ther 2010;18:251-263.
32. Kim SH, Wong RJ, Kooby DA et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer 2005;41:313-322.
33. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11- Rad50-NBS1 DNA repair complex. Nature 2002;418:348-352.
34. Kuroda S, Fujiwara T, Shirakawa Y et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010;70:9339-9348.
35. Bieler A, Mantwill K, Holzmuller R et al. Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. Radiother Oncol 2008; 86:419-427.
36. Geoerger B, Grill J, Opolon P et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 2003;89:577-584.
37. Tobias A, Ahmed A, Moon KS et al. The art of gene therapy for glioma: A review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 2013;84:213-222.
38. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials: Why do most phase III clinical trials fail? Curr Gene Ther 2009;9:368-374.
39. Zhao D, Najbauer J, Garcia E et al. Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res 2008;6:1819-1829.
40. Heidenreich R, Machein M, Nicolaus A et al. Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int J Cancer 2004;111:348-357.
41. Schmidt NO, Przylecki W, Yang W et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 2005;7:623-629.
42. Zhang H, Vutskits L, Pepper MS et al. VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. J Cell Biol 2003;163: 1375-1384.
43. Bloch O, Han SJ, Cha S et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. J Neurosurg 2012;117:1032-1038.
44. Helleday T, Petermann E, Lundin C et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
45. Petrini JH. The mammalian Mre11- Rad50-nbs1 protein complex: Integration of functions in the cellular DNA-damage response. Am J Hum Genet 1999;64:1264-1269.
46. Karen KA, Hoey PJ, Young CS et al. Temporal regulation of the Mre11-Rad50-Nbs1 complex during adenovirus infection. J Virol 2009;83:4565-4573.
47. Hart LS, Yannone SM, Naczki C et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem 2005;280:1474-1481.